Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805307/0/en/Cartesian-Therapeutics-Highlights-Progress-and-2024-Strategic-Priorities-Across-Innovative-Pipeline-of-mRNA-Cell-Therapies-for-Autoimmunity.html

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024

Read more at globenewswire.com

Related news for (RNAC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.